Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of CYT387, a potent JAK1/2 inhibitor, in patients with high- or intermediate-risk primary or post-polycythemia vera/ess...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2013
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3677140/
https://ncbi.nlm.nih.gov/pubmed/23459451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.71
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg